Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PneumoBlast
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : R4D Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration
Details : The partnership will pave the way for clinical studies of PneumoBlast™ in Brazil as a unique treatment of acute respiratory distress syndrome (ARDS) for patients affected by COVID-19, in parallel to clinical studies in the United States upon approval b...
Product Name : PneumoBlast
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 01, 2020
Lead Product(s) : PneumoBlast
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : R4D Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : PneumoBlast
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting
Details : Study showed that was observed that treatment of activated monocytes with PneumoBlast™ resulted in a 77% reduction of tissue factor expression as compared to untreated monocytes.
Product Name : PneumoBlast
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 12, 2020
Lead Product(s) : PneumoBlast
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PneumoBlast
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company scientists have demonstrated the administration and use of PneumoBlast™ induced a 51% reduction of lung fibrosis, which was statistically significant.
Product Name : PneumoBlast
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 21, 2020
Lead Product(s) : PneumoBlast
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PneumoBlast
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FibroGenesis Reports COVID-19 Breakthrough Using Fibroblast Cell Therapy (Pre-Clinical Trial Phase)
Details : Administration of PneumoBlast™ resulted in significant reduction in lung fluid accumulation in mice stimulated to enter hyper-activation mode. Also, reduction was observed from inflammatory cells, as well as suppression of chemical mediators such as in...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 21, 2020
Lead Product(s) : PneumoBlast
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fibroblast cells,Hydroxychloroquine Sulphate,Peptides
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company reports potent synergy between its fibroblast-based cell therapy and hydroxychloroquine .
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 01, 2020
Lead Product(s) : Fibroblast cells,Hydroxychloroquine Sulphate,Peptides
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable